Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models

Yuichiro Mita, Kaho Nakayama, Shogo Inari, Yukina Nishito, Yuya Yoshioka, Naoko Sakai, Kanade Sotani, Takahiro Nagamura, Yuki Kuzuhara, Kumi Inagaki, Miki Iwasaki, Hirofumi Misu, Masaya Ikegawa, Toshinari Takamura, Noriko Noguchi and Yoshiro Saito ()
Additional contact information
Yuichiro Mita: Doshisha University
Kaho Nakayama: Doshisha University
Shogo Inari: Doshisha University
Yukina Nishito: Doshisha University
Yuya Yoshioka: Doshisha University
Naoko Sakai: Doshisha University
Kanade Sotani: Doshisha University
Takahiro Nagamura: Doshisha University
Yuki Kuzuhara: Doshisha University,
Kumi Inagaki: Doshisha University
Miki Iwasaki: Doshisha University
Hirofumi Misu: Kanazawa University Graduate School of Medical Sciences
Masaya Ikegawa: Doshisha University,
Toshinari Takamura: Kanazawa University Graduate School of Medical Sciences
Noriko Noguchi: Doshisha University
Yoshiro Saito: Doshisha University

Nature Communications, 2017, vol. 8, issue 1, 1-17

Abstract: Abstract Selenoprotein P (SeP) functions as a selenium (Se)-supply protein. SeP is identified as a hepatokine, promoting insulin resistance in type 2 diabetes. Thus, the suppression of Se-supply activity of SeP might improve glucose metabolism. Here, we develop an anti-human SeP monoclonal antibody AE2 as with neutralizing activity against SeP. Administration of AE2 to mice significantly improves glucose intolerance and insulin resistance that are induced by human SeP administration. Furthermore, excess SeP administration significantly decreases pancreas insulin levels and high glucose-induced insulin secretion, which are improved by AE2 administration. Epitope mapping reveals that AE2 recognizes a region of human SeP adjacent to the first histidine-rich region (FHR). A polyclonal antibody against the mouse SeP FHR improves glucose intolerance and insulin secretion in a mouse model of diabetes. This report describes a novel molecular strategy for the development of type 2 diabetes therapeutics targeting SeP.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-017-01863-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-01863-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-017-01863-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().